In vitro and in vivo effects of selenium and selenium with vitamin E on platelet functions in diabetic rats relationship to platelet sorbitol and fatty acid distribution.
In vitro 30 min of incubation with selenomethionine (Sm) + vitamin E multiplied by about five platelet selenium (Se) decreased significantly platelet thrombin and ADP-induced aggregation decrease. Four groups of streptozotocin-induced diabetic rats were fed with a supplemented purified diet with an Se-rich yeast (Selenion): DSel, Sm: DSm, Sm alpha-tocopherol: DSmE or unsupplemented diet: D. After 24 wk of supplementation, only a decrease in thrombin-induced aggregation in group DSel compared to DSm and DSmE and D was observed. However, after 24 wk of diet compared to 14 wk, in group D and DSm, a significant increase in thrombin-induced aggregation occurred (p < 0.0001), whereas a significant decrease in groups DSel and DSmE (p < 0.0001, p < 0.03) was noted. After 21 wk of diet, in DSmE, platelet adhesion to fibronectin was significantly decreased compared to group D (p < 0.05). These changes in DSmE were associated with a significant decrease in platelet sorbitol (p < 0.02) and a very significant increase in platelet Se (p < 0.0005). Sm associated with vitamin E would appear more efficient to prevent oxidative damage of diabetic platelet membrane and thus to modulate its hyperactivity.
Douillet
C
C
National Institute of Health and Medical Research, Unit 331, Bron, France.
Bost
M
M
Accominotti
M
M
Borson-Chazot
F
F
Ciavatti
M
M
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001792:Blood Platelets / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D002851:Chromatography, High Pressure Liquid; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D004195:Disease Models, Animal; D004357:Drug Synergism; D005227:Fatty Acids / Q000097:blood*; D005527:Food, Fortified; D016014:Linear Models; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012643:Selenium / Q000097:blood; D012645:Selenomethionine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013012:Sorbitol / Q000097:blood*; D013917:Thrombin / Q000494:pharmacology; D014810:Vitamin E / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D005227:Fatty Acids; D010975:Platelet Aggregation Inhibitors; D014810:Vitamin E; D013012:Sorbitol; D000244:Adenosine Diphosphate; D012645:Selenomethionine; D013917:Thrombin; D012643:Selenium